<i>STK11</i> as an Emerging Biomarker in Non-Small Cell Lung Cancer
Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment; however, durable responses occur in only a subset of patients, underscoring the need for robust predictive biomarkers. Serine/threonine kinase 11 (<i>STK11</i>) is an emerging biomarker that portends p...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
MDPI AG
2026-04-01
|
| Cyfres: | Current Oncology |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.mdpi.com/1718-7729/33/5/241 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|